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Introduction
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS). Both genetic and environmental factors are involved in the pathogenesis of MS (Compston and Coles, 2008) . A well established environmental risk factor is a poor vitamin D status (Ascherio et al., 2010) . It is speculated that vitamin D is important in the maintenance of peripheral T cell homeostasis and thus selftolerance. In particular, in the early inflammatory phase of relapsingremitting (RR) MS, T cell homeostasis is disturbed (Venken et al., 2006; Compston and Coles, 2008) . Although regulatory T cells (Treg) are normal in number, they are functionally deficit, eventually enabling pathogenic T helper (Th) 17 and Th1 effector functions (Viglietta et al., 2004; Haas et al., 2005; Venken et al., 2006) . In vitro studies showed that vitamin D can induce regulatory T cells, shifts the Th1/Th2 balance in favor of Th2 cells, and inhibits differentiation into Th17 cells (as reviewed by Peelen et al., 2011) . In a cross-sectional study, we demonstrated that the vitamin D status of RRMS patients correlated negatively with the peripheral Th1/Th2 ratio, while a positive correlation with Treg function, but not number, was observed (Smolders et al., 2009) . High dose vitamin D supplementation in healthy controls has been shown to induce a marginal increase in Treg number (Prietl et al., 2010) . However, we could not reproduce this finding in RRMS patients, but we found a reduced Th1/Th2 ratio and an increased proportion of IL-10 + CD4 + T cells (Smolders et al., 2010) .
Recently, it became apparent that Tregs can be divided in two subsets based on the expression of CD39, a membrane bound ectonucleotidase (Borsellino et al., 2007) . CD39 + Tregs, but not CD39 − Tregs, have the potential to suppress the pathogenic IL-17 producing CD4 + T cells (Fletcher et al., 2009) . CD39 − Tregs, on the other hand, are able to produce IL-17 themselves (Fletcher et al., 2009) . Interestingly, CD39 + Treg numbers have been reported to be reduced in RRMS patients as compared to healthy controls (Borsellino et al., 2007; Fletcher et al., 2009 (Fletcher et al., 2009 2. Methods
Patients and blood samples
Thirty-two RRMS patients in remission, 22 RRMS patients during a relapse, and 30 healthy controls, matched for age and gender with the RRMS patients in remission, were enrolled in this study. All MS patients were retrieved from the Academic MS Center Limburg at Orbis Medical Center (Sittard, the Netherlands) and had a relapsingremitting (RRMS) disease course, as defined by the revised McDonald criteria (Polman et al., 2005) . A relapse was defined as occurrence of new symptoms which lasted at least 24 h and which required treatment with intravenous methylprednisolone. Blood sampling in the relapse patients took place before methylprednisolone infusion. Seven patients from the relapse cohort were analyzed again after recovery from the relapse. All blood samples for T cell phenotyping and vitamin D analyses were retrieved simultaneously. Written informed consent was obtained from each study subject and this study was approved by the regional ethical committee 'Atrium-Orbis-Zuyd'.
Population characteristics are depicted in Table 1 . Disease duration was b6 years and patients had to be in remission for >6 weeks before inclusion in the MS remission cohort. For inclusion in this study, MS patients were allowed to use Beta Interferon (IFN-β) 1a or 1b, but no other disease modulating drugs. Eighteen patients (56.3%) of the MS remission and 10 patients (45.5%) of the MS relapse cohort were on IFN-β therapy.
Serum 25(OH)D assessment
Immediately after sampling, the serum was stored at − 20°C till analysis. Serum 25(OH)D levels (vitamin D status) were determined with a radioimmunoassay kit (Immunodiagnostic Systems, Boldon, UK).
T cell phenotyping
Peripheral blood mononuclear cells (PBMC) were isolated using Ficoll density gradient centrifugation (Histopaque; Sigma Aldrich, Zwijndrecht, The Netherlands). Surface staining was performed with anti-CD3-Horizon V450, anti-CD4-APC-H7, anti-CD25-PE-Cy7 (all BD Biosciences, Breda, Netherlands), anti-CD127-FITC and anti-CD39-APC (all eBiosciences, Halle-Zoersel, Belgie). Tregs were defined as CD4 + CD25 high CD127 low cells (Liu et al., 2006; Seddiki et al., 2006) .
We have previously shown that these Tregs have a suppressive capacity (Smolders et al., 2009; Smolders et al., 2010) . The CD4 + T cell cytokine profile was assessed by intracellular cytokine expression of CD3 + CD8 − lymphocytes, i.e. CD4 + T cells, as described before (Smolders et al., 2010) . In short, PBMC were stimulated for 5 h with 1 μg/mL calcium ionomycine (Sigma Aldrich) and 50 ng/mL PMA (Sigma Aldrich) and cytokine secretion was blocked with monensin (BD Biosciences) for 5 h. Cells were stained extracellularly with anti-CD3-horizon V450 and anti-CD8-APC-H7 (BD Biosciences) and intracellularly with anti-IL-17A-PerCP-Cy5.5 and anti-CD69-PE-Cy7 (all Biolegend, Uithoorn, Netherlands). CD69 expression was included to confirm the activation status of the cells. All samples were acquired on a FACS Canto II flowcytometer (BD Biosciences) and data were analyzed with FACS Diva software.
Statistics
Statistical analysis was performed with Statistical Package for Social Sciences version 15.0 software (SPSS inc., Chicago IL, USA). Results are presented as median with corresponding interquartile range (IQR) for continues variables. Differences between groups were tested using the Mann-Whitney U test. Correlations were tested with the Spearman correlation. To compare percentages of cell subsets in RRMS patients during relapse and subsequent remission, the Wilcoxon Signed Ranks test was performed. A cut-off point based on IL-17 + CD4 + T cell percentages from MS patients in remission compared to healthy subjects was calculated using the receiver operating characteristic (ROC) curve analyses. Differences between the groups in IL-17 + CD4 + T cell percentages above and underneath
the cut-off were tested using the Chi-squared test. A p-value b0.05 was considered statistically significant.
Results

CD39 + Tregs in RRMS patients in remission and during a relapse
The percentages of total Tregs, defined as the relative amount of CD25 high CD127 low T cells within the CD4 + T cell population, did not differ significantly between HC (4.8%, 4.0-5.4), MS patients in remission (4.9%, 3.9-6.7) and MS patients during relapse (5.3%, 4.1-6.3). Since CD39 expression discriminates between two distinct Treg subsets, we next analyzed the fraction CD39 + cells within the Treg population as well as the relative amount of CD39 expressing Tregs within the CD4 + T cell population (Fig. 1 ). The latter may be more relevant as outcome measure since, at least in vitro, the ratio between Tregs and responder T cells is used to determine Treg function. The fraction CD39 + Tregs (% of CD4 + T cells) was not different for HC
(1.8%, 1.2-2.6), MS patients in remission (2.1%, 1.3-2.9) and MS patients during relapse (1.7%, 0.6-2.8) (Fig. 1B) . Similar results were obtained when the CD39 + cells were analyzed within the Treg population ( Fig. 1C) . Interestingly, the latter analysis revealed a dichotomy in the relapse cohort. Nine patients had a percentage of CD39 + cells within the Treg population close to the median value of the HC and the MS patients in remission, while 13 patients had very low percentages of CD39 + cells within the Treg population (Fig. 1C) . The dichotomy in the distribution of CD39 + cells within the Treg population could not be explained by differences in the severity of the relapse (objective/subjective or sensible/motor function or presence of optic neuritis). Next, we analyzed whether the percentage of CD39 + cells within the Treg population normalized when the MS patients were again in remission. Seven patients were re-analyzed while in remission, 3 to 9 months after the relapse. The results revealed that the percentage of CD39 + cells within the Treg population was stable in time ( Fig. 1D) . Therefore, the dichotomy might be explained by previous disease activity parameters. However, there was no association with disease duration, EDSS score before relapse, time since last relapse, relapse rate, or number of relapses since onset of the disease, neither with use of medication, gender, or age (data not shown). (Fig. 2A) . However, using a cut-off value of 1.05% (as determined by ROC curve analysis), 37.5% of the MS patients in remission and 45.5% of the MS patients during a relapse versus 3.3% of the healthy controls had an elevated percentage of IL-17 + cells within the CD4 + T cell population (p b 0.01; Fig. 2A ). In the MS remission cohort, the IL-17 + CD4 + T cell fraction correlated positively with the fraction of CD39 + Tregs within the CD4 + T cell population (r = 0.468, p = 0.007; Fig. 2B ). No such association was observed in the MS relapse (Fig. 2C) or the HC cohort (Fig. 2D) (Fig. 3A-C) .
However, in the MS remission cohort, the patients with an elevated percentage of Th17 cells (>1.05%) tended to have lower vitamin D levels as compared to those without an expanded Th17 population (p = 0.059). Surprisingly, a negative correlation of serum 25(OH)D levels with the CD39 + Treg fraction was observed in the MS remission cohort (r = −0.399, p = 0.024; Fig. 3D ), while no correlation was found in the MS relapse (Fig. 3E) or the healthy control cohort (Fig. 3F) .
Discussion
The present cross-sectional study revealed three interesting findings. First, although CD39 + Treg percentages were similar in MS patients in remission or during a relapse and healthy controls, CD39 (Fletcher et al., 2009) , unlike the CD39 − Tregs (Fletcher et al., 2009; Dwyer et al., 2010) . Recently, Ye et al. (2011a Ye et al. ( , 2011b In this study, we demonstrated that CD39 + Treg percentages are comparable between HC and MS patients both in remission and during a relapse. In contrast, three previous studies reported reduced CD39 + Treg percentages in RRMS patients during remission (Borsellino et al., 2007; Fletcher et al., 2009; Libera et al., 2011) , while CD39 + Treg percentages during a relapse were in line with our data (Libera et al., 2011) . The discrepancies between our data and the former studies with regard to CD39 + Treg percentages in RRMS patients during remission might first be explained by Treg definition. Two studies used a less stringent Treg definition, CD4 + CD25 high CD39 + percentages (Borsellino et al., 2007; Libera et al., 2011 ), compared to our paper. Moreover, Libera et al. defined their CD39 + Tregs as percentages of total PBMC population. In another paper, Tregs were defined as CD4 + CD25 high CD127 low FoxP3 + T cell percentages (Fletcher et al., 2009) . Secondly, population characteristics of the RRMS study cohorts might differ importantly between the different studies. In the studies of Borsellino et al. (2007) and Fletcher et al. (2009) , MS patients did not use any immune modulatory medication at the moment of inclusion, while the majority of the MS patients in our study used IFN-β. Furthermore, the disease duration in one study (Libera et al., 2011 ) is longer compared to the disease duration of our MS patients. In the other two studies, the disease duration was not mentioned (Borsellino et al., 2007; Fletcher et al., 2009 ). Finally, Fletcher et al. (2009) compared the MS cohort to a healthy control cohort, but information about possible matching with the disease cohort was not provided. In the MS relapse cohort, we observed a dichotomy in CD39 + Treg percentages. The low CD39 + Treg percentages in a subgroup of the MS patients during a relapse could imply a lower capacity to suppress IL-17 secreting CD4 + T cells, a T cell population that is believed to be pathogenic in MS. Therefore, a relation between CD39 + Treg percentages and disease severity or duration or relapse rate was investigated. However, CD39 + Treg percentages were not related to any patient characteristic. Another possibility is that CD39 is downregulated, like CD28 on CD4 + T cells (Bryl et al., 2001) , upon excessive activation of the Tregs by the repeating occurrence of relapses. Hence, CD39 + Treg percentages might be associated with the total number of relapses. However, we did not find such an association. CD39 + Treg percentages were also assessed after recovery from the relapse. We showed that CD39 + Treg percentages are stable in time, since low percentages of CD39 + Tregs are not restored in remission.
These data indicate that fluctuations in CD39 + Treg percentages do not account for the observed dichotomy. Altogether, we have not been able to explain the dichotomy in CD39 + Treg percentages in the relapse cohort and can therefore not exclude the possibility that this finding was based on coincidence. Th17 cells are considered to be important in MS pathogenesis (Kebir et al., 2007; Steinman, 2007) . In contrast to Durelli et al. (2009) , we observed no difference in median Th17 cell frequencies between MS patients and healthy controls. However, we demonstrated that about 40% of the MS patients during a relapse as well as in remission had an increased frequency of Th17 cells. These results imply a disturbance in the regulation of Th17 cells in these MS patients. Here, we investigated the relation between circulating CD39 + Tregs and Th17 cells. In the MS remission cohort, but not in the MS relapse cohort, we observed that higher IL-17 + CD4 + T cell percentages were accompanied by higher CD39 + Treg percentages. Since CD39 + Tregs have been shown to have the ability to suppress Th17 cells, the observed positive correlation in the MS remission cohort may reflect a mechanism to compensate for the expanded Th17 subset. Interestingly, in MS patients during a relapse, expansion of the Th17 cell population is not counterbalanced by an expansion in CD39 + Treg percentages. We speculate that this defective regulation of Th17 cells might contribute to the development of an exacerbation of disease. Recently, Wilson et al. (2011) , showed that an adenosine analog, in combination with IL-6, is able to induce Th17 cells. Adenosine is a molecule that is produced upon conversion of adenosine triphosphate (ATP) by CD39 in combination with CD73 (Bours et al., 2006) . A fraction of CD39 + Tregs has been shown to co-express CD73 (Alam et al., 2009; Mandapathil et al., 2010 The strength of our study is that we are, to our knowledge, the first to connect the vitamin D status with CD39 + Treg percentages in a cross sectional study. In addition, we were able to compare CD39 + Treg percentages and associations with other parameters both during quiescent and active RRMS. However, this study has some short comings. The cross sectional study design does not allow to draw conclusions with respect to causality. Furthermore, we assessed CD39 numbers. Also in case of conventional Tregs, a correlation was only observed with vitamin D status when analyzing the function of these cells (Smolders et al., 2009) . Therefore, it would be interesting to study CD39 + Treg function in future studies.
In conclusion, the control of Th17 cells seems to be disturbed in MS patients. MS patients in remission seem able to cope with this disturbance by a counterbalanced expansion of CD39 
